You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

271 Results
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
DOXOrubicin,
trabectedin (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
pegaspargase (PDRP prior authorization),
gemcitabine,
oxaliplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daSATinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    ribociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant according to clinical criteria
ODB - General Benefit
    letrozole
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
letrozole,
ribociclib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Sep 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
Exceptional Access Program
    abemaciclib - For the adjuvant treatment, in combination with endocrine therapy, of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence, according to criteria
ODB - General Benefit
    tamoxifen
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
abemaciclib,
tamoxifen
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
binimetinib (Unfunded),
encorafenib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
iBRUtinib (Unfunded),
venetoclax (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
DOCEtaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    tamoxifen
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
tamoxifen,
ribociclib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Sep 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    niraparib / abiraterone - For the treatment of metastatic castration resistant prostate cancer in patients with a BRCA mutation
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
niraparib / abiraterone,
prednisone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For the treatment of patients with chronic lymphocytic leukemia (CLL), in combination with venetoclax, based on criteria
Exceptional Access Program
    venetoclax - For the treatment of patients with chronic lymphocytic leukemia (CLL), in combination with ibrutinib, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iBRUtinib,
venetoclax
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
brentuximab vedotin (Unfunded),
DOXOrubicin,
cyclophosphamide,
etoposide,
dacarbazine,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025

Pages